Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ricc A/S manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner and 1 distinct art unit, focusing the company's current legal interactions. This level of focus suggests that the company is prioritizing a specific biotechnological advancement in its active docket. The pending office action represents the current focus of the company's intellectual property development.
The busiest examiner for the company is VANHORN, ABIGAIL LOUISE, who is responsible for 1 busiest examiner pending office action. The progress of the company's active docket depends on the specific review provided by this examiner. Practitioners should evaluate the examiner's previous rulings in the Biotechnology & Pharmaceuticals field to prepare effective responses. The success of the 1 pending office action will determine the company's immediate progress in securing patent rights. Navigating the requirements of this specific examiner is the most critical task for the company's current prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001098 | Guanosine Analogues for Use in Therapeutics Polynucleotides | VANHORN, ABIGAIL LOUISE | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001098 | Guanosine Analogues for Use in Therapeutics Polynucleotides | VANHORN, ABIGAIL LOUISE | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001098 | Guanosine Analogues for Use in Therapeutics Polynucleotides | VANHORN, ABIGAIL LOUISE | 1636 | §103§112 | Final Rejection | 31d overdue | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRicc A/S has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Abigail Louise Vanhorn has the most, with 1 of Ricc A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.